Ann: PromarkerD clinical assay performance results published, page-8

I agree, more validation is never a bad thing.

BUT, why hasn't the company come out with a roadmap for commercialisation? How many more validations are required prior to cash flows? As an investor, I want to know how long it will take for cash flows to come in so that I can work out a return on investment (ROI). There is very little the company has provided on this front, which is dissapointing. It looks like PIQ is just aimlessly plodding along with no true end goal in site - a validation here, a validation there. A signed deal here and a signed deal there (Italy, Spain, Ireland, Dominican Republic) but no cash flows? Why not?

What is the end goal? PIQ need to let us know what the end goal is, and the path and time to acheive this.

Sorry to sound like a downer, but it is just frustrating.

Cheers.